Search research articles
Contact Us
Filters
Showing results (21-30 of 158) with videos related to
Page
of 16
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
January 26, 2024
A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia
Hagop M Kantarjian, Elias J Jabbour, Jeffrey H Lipton, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
January 25, 2021
Hematology Patient Protection During the COVID-19 Pandemic in Italy: A Nationwide Nursing Survey
Stefano Botti, Nicola Serra, Fausto Castagnetti, et al.
Biologics : Targets & Therapy
|
August 27, 2009
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
Giovanni Martinelli, Ilaria Iacobucci, Simona Soverini, et al.
Drugs
|
April 9, 2014
First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies
Gabriele Gugliotta, Fausto Castagnetti, Michela Apolinari, et al.
British Journal of Haematology
|
November 23, 2011
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457
Manuela Mancini, Michela Aluigi, Elisa Leo, et al.
British Journal of Haematology
|
August 29, 2012
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia
Elisa Leo, Manuela Mancini, Michela Aluigi, et al.
Leukemia Research
|
August 3, 2013
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors
Fabio Efficace, Gianantonio Rosti, Francesco Cottone, et al.
Leukemia Research
|
October 4, 2011
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib
Tamara Intermesoli, Fausto Castagnetti, Simona Soverini, et al.
Cellular Signalling
|
April 22, 2014
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib
Manuela Mancini, Elisa Leo, Virginia Campi, et al.
Oncotarget
|
November 21, 2017
Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia
Manuela Mancini, Simona Soverini, Gabriele Gugliotta, et al.
Page
of 16
Search research articles
Search
Showing results (21-30 of 158) with videos related to
Sort By:
Page
of 16
Clinical Lymphoma, Myeloma & Leukemia
|
January 26, 2024
A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia
Hagop M Kantarjian, Elias J Jabbour, Jeffrey H Lipton, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
January 25, 2021
Hematology Patient Protection During the COVID-19 Pandemic in Italy: A Nationwide Nursing Survey
Stefano Botti, Nicola Serra, Fausto Castagnetti, et al.
Biologics : Targets & Therapy
|
August 27, 2009
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
Giovanni Martinelli, Ilaria Iacobucci, Simona Soverini, et al.
Drugs
|
April 9, 2014
First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies
Gabriele Gugliotta, Fausto Castagnetti, Michela Apolinari, et al.
British Journal of Haematology
|
November 23, 2011
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457
Manuela Mancini, Michela Aluigi, Elisa Leo, et al.
British Journal of Haematology
|
August 29, 2012
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia
Elisa Leo, Manuela Mancini, Michela Aluigi, et al.
Leukemia Research
|
August 3, 2013
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors
Fabio Efficace, Gianantonio Rosti, Francesco Cottone, et al.
Leukemia Research
|
October 4, 2011
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib
Tamara Intermesoli, Fausto Castagnetti, Simona Soverini, et al.
Cellular Signalling
|
April 22, 2014
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib
Manuela Mancini, Elisa Leo, Virginia Campi, et al.
Oncotarget
|
November 21, 2017
Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia
Manuela Mancini, Simona Soverini, Gabriele Gugliotta, et al.
Page
of 16